The acquisition, which is due to be finalized in January 2010, will provide Synexus with eight additional research centres in Germany, as well as reinforcing its presence in Austria and Ukraine. The deal is set to boost the company’s total patient population by 100% across Europe. Speaking of the acquisition, Michael Fort, CEO of Synexus, stated, “Germany is a very, very important market, it is one of the big five pharma economies”. The deal is also set to open Synexus’ focus up to different therapeutic areas; thus helping the company to recruit patients for rheumatoid arthritis and diabetes trials.
Commenting on the acquisition, ClinPharm’s founding CEO, Dr Stahl, stated, “It was a natural fit to team up with Synexus. We know each other very well and our geographic coverage is totally complementary. Together we are much stronger and I look forward to helping the new company with further expansion which delivers real benefits to our clients in pharma.”
This move good signal a growth in pharmaceutical job opportunities in Europe. To search for jobs in Europe, click here.